Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression

DeannaLee M. Beauvais, Scott E. Nelson, Kristin M. Adams, Noah A. Stueven, Oisun Jung, and Alan C. Rapraeger

From the Department of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA

Edited by Eric Fearon

Epidermal growth factor receptor (EGFR) is a causal factor in carcinoma, yet many carcinoma patients are resistant to EGFR inhibitors. Potential insight into this resistance stems from prior work that showed EGFR in normal epithelial cells docks to the extracellular domain of the plasma membrane proteoglycan syndecan-4 (Sdc4) engaged with α3β1 and α6β4 integrins. We now report that this receptor complex is modified by the recruitment of syndecan-2 (Sdc2), the Receptor d’Origine Nantais (RON) tyrosine kinase, and the cellular signaling mediator Abelson murine leukemia viral oncogene homolog 1 (ABL1) in triple-negative breast carcinoma and head and neck squamous cell carcinoma, where it contributes to EGFR kinase–independent proliferation. Treatment with a peptide mimetic of the EGFR docking site in the extracellular domain of Sdc4 (called SSTNEGFR) disrupts the entire complex and causes a rapid, global arrest of the cell cycle. Normal epithelial cells do not recruit these additional receptors to the adhesion mechanism and are not arrested by SSTNEGFR. Although EGFR docking with Sdc4 in the tumor cells is required, cell cycle progression does not depend on EGFR kinase. Instead, progression depends on RON kinase, activated by its incorporation into the complex. RON activates ABL1, which suppresses p38 mitogen-activated protein kinase and prevents a p38-mediated signal that would otherwise arrest the cell cycle. These findings add to the growing list of receptor tyrosine kinases that support tumorigenesis when activated by their association with syndecans at sites of matrix adhesion and identify new potential targets for cancer therapy.

It is well known that cooperative signaling between adhesion receptors and receptor tyrosine kinases regulates mechanosensing, cell migration, proliferation, and survival. This cooperative signaling often emanates from adhesion sites that incorporate receptor tyrosine kinases along with integrins, cadherins, or other adhesion receptors, leading to clustering and both ligand-dependent and ligand-independent activation of the kinases (1–4). However, whereas there are numerous reports of integrins associating with receptor tyrosine kinases, the means by which these individual receptors are recognized and organized into signaling foci often remains obscure.

Syndecans contain docking sites in their extracellular domains that assemble partner receptors into signaling complexes (5–7). In addition to the syndecan, these receptor complexes typically consist of one or more integrins together with a receptor tyrosine kinase or phosphatase (5–11). Because the docking motifs in the syndecans are extracellular, peptide mimetics of these sites (called “synstatins”) can be used as tools to competitively disrupt receptor assembly and probe the importance of these specific receptor interactions. Such studies have shown that receptors organized by syndecans impact signaling critical for tumor cell migration/invasion, proliferation, and survival and/or tumor-induced angiogenesis (6–9, 12).

Syndecan-4 (Sdc4) mediates the assembly of the epidermal growth factor receptor (EGFR) with the laminin-332 (LN332)–binding α6β4 and α3β1 integrins (7, 13). Whereas the α6β4 integrin engages the Sdc4 cytoplasmic domain, coupling of EGFR and the α3β1 integrin relies on a juxtamembrane site in the Sdc4 ectodomain (amino acids 87–131 in humans), which is blocked by a peptide mimetic now called “synstatin-EGFR” (SSTNEGFR) (13). This peptide blocks the epidermal growth factor (EGF)-stimulated migration of keratinocytes and mammary epithelial cells on LN332 that the cells deposit as they migrate (7, 13).

EGFR has been implicated in multiple human cancers, including carcinomas of the head and neck and breast (14–16). EGFR and its ligands (e.g., EGF, transforming growth factor-alpha) are overexpressed in up to 90% of head and neck cancer patients (17–19), are further induced by standard of care external beam radiation and DNA damaging agents (20–22), and are strongly linked to tumor progression (23, 24). EGFR is also a causal agent in triple-negative breast carcinoma (TNBC), a highly malignant form that comprises 15% to 25% of breast cancers (25, 26). Nonetheless, EGFR inhibitors, including the EGFR-blocking antibody cetuximab or EGFR kinase inhibitors, have had disappointing outcomes in the clinic (17, 27), suggesting alternative mechanisms through which EGFR promotes or sustains the progression of these cancers. Accordingly, we subjected head and neck squamous cell carcinoma (HNSCC) and TNBC cells for treatment with

* For correspondence: Alan C. Rapraeger, rapraeger@humonc.wisc.edu.
SSTN<sub>EGFR</sub> blocks carcinoma proliferation

SSTN<sub>EGFR</sub> to probe the involvement of Sdc4 as a partner in EGFR signaling in these cancers. We find that SSTN<sub>EGFR</sub> induces a rapid and global cell cycle arrest in HNSCC and TNBC cells, including an S-phase arrest; this is unusual because, although growth factor receptors may be required to enter S-phase, their signaling is not thought to be required once S-phase is begun. We also find that nontransformed oral or mammary epithelial cells are refractory to proliferation arrest by SSTN<sub>EGFR</sub>, making its inhibition highly specific for tumor cells. Furthermore, although EGFR is required in this regulatory mechanism, its kinase activity is not. Instead, cell cycle progression depends upon active receptor d’origine nantais (RON) (also known as macrophage stimulating protein-1 receptor (MST1R) (28–30)) and the cytoplasmic kinase ABL1 (31), which, along with the Sdc4 homolog syndecan-2 (Sdc2) partners with Sdc4, EGFR, and the laminin-binding integrins specifically in the tumor cells. When these kinases are inactivated by their displacement from Sdc4 by SSTNEGFR, a corresponding increase in p38 mitogen-activated protein kinase (p38MAPK) occurs, presumably constitutively activated by metabolic, oncogenic, and/or genotoxic stress in the tumor cells but held in abeyance by signaling from the Sdc4 receptor complex. This suggests that an epithelial cell migration mechanism that relies on Sdc4, EGFR, and the α3β1 and α6β4 integrins adopts a dual role by incorporating Sdc2, RON, and ABL1 to sustain S-phase progression at times of cellular stress.

Results

SSTN<sub>EGFR</sub> impairs carcinoma cell proliferation

The proliferation of a panel of human TNBC and HNSCC cell lines in the presence of SSTN<sub>EGFR</sub> was compared to nontumorigenic breast, oral, and epidermal epithelial cells. Whereas the proliferation of nontumorigenic, immortalized normal oral keratinocytes (NOKs), human tonsillar epithelial cells (HTEs), mammary epithelial cells (MCF10A), and epidermal keratinocytes (HaCaT) are not affected by SSTN<sub>EGFR</sub> (Fig. 1A), the peptide causes reduced proliferation of HNSCC (Fig. 1B) and TNBC cells (Fig. 1C) with an IC<sub>50</sub> that falls with the range of 3 to 10 μM. This coincides with the approximate concentration required to displace 90% of EGFR and the α3β1 integrin from Sdc4 (13).

SSTN<sub>EGFR</sub> induces rapid cell cycle arrest

For the sake of simplicity, we elected to use a single cell line (UWSCC47 cells) to conduct exploratory studies into this growth mechanism and then extended our findings to the other transformed cells. UM-SCC47 cells and normal NOKs as a control were treated with SSTN<sub>EGFR</sub>, accompanied by labeling with the thymidine nucleoside analog 5-ethynyl-2’-deoxyuridine (EdU), to analyze DNA synthesis by flow cytometry. As expected, treated NOKs showed no significant change in EdU incorporation or in the distribution of cells throughout the cell cycle when compared to untreated cells (Fig. 2A). In contrast, an S-phase block after only 3 h treatment of UM-SCC47 cells is indicated by a complete lack of EdU incorporation (Fig. 2A), and the failure of the cells to show any major change in their distribution in the G1-, S-, G2-, and M-phases of the cell cycle suggests the peptide may induce a global block to cell cycle progression. Shorter treatment times utilizing in situ staining of fixed cells show that treatment with SSTN<sub>EGFR</sub> for as little as 1 h reduces EdU incorporation by well over 90% in HNSCC and TNBC cells, whereas NOKs and MCF10A cells show no reduction (Fig. 2B). To verify the arrest in S-phase, UM-SCC47 cells were synchronized in early S-phase using a double thymidine block, then released for 2 h to recover (Fig. 2C). Cells released for 2 h and chased for an additional 12 h with the vehicle alone progress into late S-phase/G2 or pass through G2/M and reenter G1 (Fig. 2C). In contrast, cells released for 2 h then chased for 12 h in SSTN<sub>EGFR</sub> remain entirely in S-phase and show little or no EdU incorporation above background (Fig. 2C).
An S-phase arrest in response to EGFR inhibition is uncommon, as receptor signaling is typically required to bypass the G1/S “start” point of the cell cycle but is thought to no longer be required once DNA synthesis has begun (32). Mechanisms that do cause S-phase arrest typically arise from the DNA damage response (DDR), activated either by DNA damage or replicative stress (33, 34). The DDR activates p53 and/or checkpoint kinases (e.g., Chk1 or Chk2) downstream of the DNA damage sensors (e.g., ATM, ATR, and DNA-dependent protein kinase) that phosphorylate cell cycle regulatory factors, among them the histone variant H2AX (33–35). However, UM-SCC47 or MDA-MB-231 tumor cells arrested in response to SSTN_EGFR fail to activate either Chk1 or Chk2 or cause phosphorylation of H2AX (γH2AX) (Fig. S1). This contrasts with the phosphorylation observed when they are treated with ionizing radiation or hydroxyurea (HU) to induce DNA damage or replicative stress that leads to DDR activation (35) (Fig. S1).

**Figure 2. Analysis of DNA synthesis and cell cycle progression in SSTN_EGFR.** A, NOK or UM-SCC47 cells were treated with or without 30 μM SSTN_EGFR for 3 h or 16 h, labeled with EdU and DAPI and analyzed by flow cytometry; B, transformed (UM-SCC47, UM-SCC1, MDA-MB-231, and MD-MB-468) and nontransformed (NOKs and MCF10A) epithelial cells were cultured with or without 30 μM SSTN_EGFR for 1, 3, or 6 h and then labeled with EdU. EdU incorporation is expressed as a percentage of NOKs grown in vehicle alone; C, UM-SCC47 cells were arrested at the G1/S phase interface using a double thymidine block (24 h block, 16 h release, and 24 h block), released for 2 h then subjected to 12 h treatment with either 30 μM SSTN_EGFR or vehicle alone. Cells were then labeled with EdU and DAPI and analyzed by flow cytometry; D, UM-SCC47 cells are subjected to a double thymidine or double SSTN_EGFR block (24 h block, 16 h release, and 24 h block), then released and labeled with EdU to quantify cells in S-phase; ***p ≤ 0.001. EdU, 5-ethyl-2'-deoxyuridine; NOK, normal oral keratinocyte.
**SSTN<sub>EGFR</sub> blocks carcinoma proliferation**

The apparent failure of the SSTN<sub>EGFR</sub>-arrested cells to accumulate in any one phase of the cell cycle suggests that the block is global rather than focused on any one phase. To test this, we compared the behavior of UM-SCC47 cells subjected to either a double thymidine block or a double SSTN<sub>EGFR</sub> block. The UM-SCC47 cells have a 24 h cell cycle, with an approximate 8 h S-phase, 2 h G2/M, and 14 h G1. Thus, EdU labels approximately one-third of the cells if they are not synchronized (Fig. 2D). A 24 h thymidine block arrests the one-third of the cells that are spread throughout S-phase, whereas the rest progress to the G1/S start before arresting. A subsequent 16 h release allows these and the cells arrested throughout S-phase to progress through and exit S-phase and enter G1. Reimposition of a second 24 h thymidine block at this point prevents these cells from entering S-phase and they arrest as a cohort at the G1/S interface. Cells labeled at this point show no EdU incorporation (0 h), but cells released for 4 or 6 h transit partially through S-phase, as shown by extensive (greater than 80%) EdU labeling (Fig. 2D). This contrasts with the result seen if the cells are subjected to a 24 h double SSTN<sub>EGFR</sub> block (Fig. 2D). The cells show no labeling for 1 h after SSTN<sub>EGFR</sub> removal, but at 2, 4, or 6 h after release, approximately one-third of the cells incorporate EdU, the same as cells treated with vehicle alone, indicating that the number of cells in S-phase at any of these time points remains the same (Fig. 2D). There is no increase in cells entering S-phase, suggesting that cells have not piled up at the G1/S-phase boundary despite the ability of SSTN<sub>EGFR</sub> to arrest cells in S-phase (Fig. 2C) nor have cells entering S-phase been delayed by a block elsewhere. Instead, the cells appear to globally arrest wherever they are in the cell cycle when SSTN<sub>EGFR</sub> is applied and then recover and resume their transit when SSTN<sub>EGFR</sub> is removed.

**Cell cycle progression depends on active RON and ABL1 kinases**

We have shown previously that EGFR-stimulated migration of HaCaT and MCF10A epithelial cells on LN332 depends on its coupling with the α3β1 and α6β4 integrins by Sdc4 and requires EGF and active EGFR kinase (7, 13). Similarly, EGFR-stimulated migration of NOKs or UM-SCC47 cells through LN332-coated filters is blocked by EGFR kinase inhibitors (gefitinib or erlotinib), SSTN<sub>EGFR</sub> or α3β1 integrin blocking antibody (Fig. 3A). In contrast, the proliferation of NOKs or UM-SCC47 cells is independent of EGFR kinase activity, shown by the failure of gefitinib and erlotinib to block EdU incorporation even when used at 100-fold over their IC<sub>50</sub> (Fig. 3B). But, consistent with the proliferation inhibition observed in Figure 1, the UM-SCC47 failed to incorporate EdU in the presence of SSTN<sub>EGFR</sub> and the addition of EGF cannot reverse the block to EdU incorporation by SSTN<sub>EGFR</sub> in the UM-SCC47 tumor cells (Fig. 3B).

These findings prompted us to question the potential role of other kinases in the arrest mechanism. Like EGFR (7, 13, 36), RON is reported to associate with the α6β4 integrin (37, 38), although whether this association is direct or mediated by a syndecan has not been investigated. Accordingly, we tested kinase inhibitors specific for RON (CAS 913376-84-8 and BMS-777607). We also tested GNF-5 and PPY-A, kinase inhibitors specific for ABL1, a cytoplasmic kinase known to be activated by RON (39, 40) and found that inhibiting either kinase mimics the effects of SSTN<sub>EGFR</sub> by significantly reducing EdU incorporation in HNSCC and TNBC cells, but not in NOKs or MCF10A cells (Fig. 3C). Focusing on the UM-SCC47 cells, we find that RON and ABL1 are active in the tumor cells, as evidenced by phosphorylation of Y1238/1239 and Y412 in their respective kinase domains, as well as Y245 in the SH2-kinase linker of ABL1 (29, 41) (Fig. 3D). This phosphorylation is blocked by SSTN<sub>EGFR</sub> and ABL1 no longer associates with RON (Fig. 3D). This suggests that by interacting with Sdc4, either directly or indirectly, RON is activated via transphosphorylation when clustered, engages the ABL1 SH2 domain, and activates ABL1 by phosphorylation.

Probing Sdc4 immunoprecipitates from UM-SCC47 cells confirms that active RON and active ABL1 coprecipitate with Sdc4 (Fig. 4A), along with EGFR, the α3β1 integrin, phosphorylated α6β4 integrin, the CD151 tetraspanin known to associate with the α3β1 and α6β4 integrins (42–48), and Sdc2–Sdc4 homolog (49). All are displaced by SSTN<sub>EGFR</sub> with the exception of the α6β4 integrin, which remains engaged with Sdc4 via its cytoplasmic domain (13) but is no longer phosphorylated (Fig. 4A). This recapitulates prior findings that phosphorylation of the α6β4 integrin depends on kinases in the receptor complex that are activated by syndecan clustering (13, 36, 50). Immunoprecipitation of Sdc2 captures the same cohort of receptors (Fig. 4A), strongly suggesting that they are all in a single receptor complex. SSTN<sub>EGFR</sub> displaces all but RON from Sdc2 (Fig. 4A), although RON is no longer phosphorylated, explaining the loss of ABL1 as well. This suggests that RON relies on Sdc2 for its linkage to the receptor complex, potentially via an interaction involving the Sdc2 extracellular domain. To confirm this, the receptors that assemble together by docking, either directly or indirectly, with the Sdc4 extracellular domain (namely, Sdc2, EGFR, CD151, α3β1 integrin, and RON) were captured using GST-S4ED, a recombinant Sdc4 extracellular domain fusion protein (Fig. 4B); performing this capture in the presence of recombinant His-tagged Sdc2 extracellular domain as a competitor prevents capture of Sdc2 and RON (Fig. 4B).

The incorporation of Sdc2, RON, and ABL1 into the receptor complex in tumor cells contrasts with the makeup of the complex in nontumorigenic cells; originally defined in HaCaT cells, Sdc4 immunoprecipitates contain EGFR and α6β4 and α3β1 integrins that the HaCaT cells use for migration on LN332 (7, 13). These precipitates do not contain Sdc2 and RON, although these receptors are expressed by the cells (Fig. 4C). These findings suggest that in tumor cells, Sdc2 becomes incorporated into the receptor complex involved in cell adhesion and migration and extends its activity to a mechanism that sustains cell proliferation as well (model Fig. 4D).

The lack of a requirement for EGFR kinase activity in the cell proliferation mechanism raises the question of what role, if
any, EGFR has in this receptor complex. Silencing EGFR expression blocks assembly of the entire complex with Sdc4 except for the α6β4 integrin that remains bound via its cytoplasmic domain and CD151 that is known to associate with the integrin (Figs. 4E and S2B), revealing a major structural role for EGFR. Silencing α3β1 integrin expression does not affect the assembly of this core set of receptors, but it does prevent the capture of Sdc2 and Sdc2-associated RON kinase (Figs. 4E and S2B). Furthermore, silencing either CD151 or α6β4 integrin has no effect on EGFR engaging Sdc4 but does block the assembly of the adhesion receptor complex consisting of α3β1, α6β4, and CD151 with EGFR (Figs. 4E and S2B). Control siRNA has no effect on the assembly of the receptor complex (Fig. S2B) or expression of the complex’s component receptors (Fig. S2A). Moreover, each receptor siRNA is target-specific with no off-target effects on expression of other components within the complex (Fig. S2A). These findings provide a general order of assembly as shown in Figure 4D, with EGFR

*SST*$_{EGFR}$ blocks carcinoma proliferation

Figure 3. Comparison of cell migration versus proliferation in the presence of SST$_{NEGFR}$, EGFR kinase inhibitors, or kinase inhibitors specific for RON or ABL1. A, NOK or UM-SCC47 HNSCC cells were induced to migrate across LN332-coated filters in the presence or absence of 10 ng/ml EFG or 10 ng/ml EGF together with 30 μM SST$_{NEGFR}$, 3 μM gefitinib, 2 μM erlotinib, or 10 μg/ml α3β1 blocking antibody (P1B5) (Bar = 50 μM). Migration is quantified and expressed as percent of migration relative to EGFR-stimulated cells; B, UM-SCC47 HNSCC or NOKs grown in complete culture medium were treated for 3 h with 30 μM SST$_{NEGFR}$, 3 μM gefitinib, or 2 μM erlotinib, then fixed and stained with EdU and DAPI to quantify the percentage of cells synthesizing new DNA relative to control cells treated with vehicle alone. Arrow highlights the decreased proliferation of UM-SCC47 cells in SST$_{NEGFR}$. Representative pictures show untreated versus treated UM-SCC47 cells, including a cohort treated with 30 μM SST$_{NEGFR}$ supplemented with 10 ng/ml EGF (Bar = 50 μM); C, normal epithelial cells (NOKs, MCF10A), HNSCC cells (UM-SCC47, UM-SCC1), and TNBC cells (MB-468, MB-231) were grown for 3 h in complete culture medium containing RON kinase inhibitors (1 μM CAS 913376-84-8 or 3 μM BMS-776707) or ABL1 inhibitors (2 μM GNF5 or 0.2 μM PPY-A) followed by EdU labeling and quantification relative to control cells treated with vehicle alone; D, UM-SCC47 cells were treated for 3 h with vehicle or 30 μM SST$_{NEGFR}$, then lysed and the cell lysates were either (i) subjected to immunoprecipitation with nonspecific isotype control goat IgG or goat polyclonal anti-RON antibody (1 μg AF691/1 mg input) and analyzed on Western blots for total and active (pY1238/pY1239) RON and total and active (pY245 and pY412) ABL1 or (ii) analyzed on Western blots for active (pY245 or pY412) ABL1; **p ≤ 0.01, ***p ≤ 0.001. EdU, 5-ethynyl-2'-deoxyuridine; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; LN332, laminin-332; NOK, normal oral keratinocytes; RON, recepteur de l'origine nantais; TNBC, triple-negative breast cancer.
providing a link between Sdc4 and a complex of CD151 and the integrins and Sdc2 linking RON to this complex via an as-yet undefined interaction of the Sdc2 extracellular domain. Each member of the receptor complex appears to play an essential role either in assembly of the receptor complex or in signaling because silencing expression of any one of the receptors or kinases (e.g., Sdc4, Sdc2, EGFR, RON, α3β1 integrin, α6β4 integrin, CD151, or ABL1) results in cessation of DNA synthesis by well over 90% in UM-SCC47 cells (Fig. 4F).

**Cell surface expression of cell cycle regulatory receptors is upregulated by carcinoma cells**

Analysis of receptor expression on representative carcinoma cell lines demonstrates that all express the critical signaling and adhesion receptors of the Sdc4-organized complex at the cell surface (Fig. 5A). This contrasts with nontransformed epithelial cells. HaCaT cells express cell surface Sdc4, EGFR, α3β1 integrin, and α6β4 integrin but have undetectable levels of cell surface RON and Sdc2 despite the presence of these

---

**Figure 4. Identification of signaling receptors required for S-phase progression.** A, UM-SCC47 cells treated with vehicle alone or 30 μM SSTNEGFR for 3 h were lysed and subjected to immunoprecipitation with nonspecific, isotype-matched control IgG, and mAb BG3 to Sdc4 or rabbit polyclonal antibody to Sdc2. Immunoprecipitates were probed for the presence of EGFR, α3 integrin (ITGA3), β4 integrin (ITGB4), phosphorylated ITGB4 with PY20, CD151, total and active RON (pY1238/1239), total and active ABL1 (pY412 and pY245), and Sdc2 and Sdc4; B, GST-S4ED immobilized on glutathione beads was incubated with UM-SCC47 whole-cell lysates overnight in the presence or absence of 30 μM His-tagged S2ED and the receptors captured by S4ED were analyzed by Western blot; C, Sdc4 immunoprecipitates from HaCaT whole-cell lysates were probed for associated α3 integrin (ITGA3), β4 integrin (ITGB4), EGFR, RON, and Sdc2 via Western blot. RON and Sdc2 levels in the total lysate are shown. D, model showing proposed order of receptor complex assembly. E, UM-SCC47 cells transfected for 72 h with siRNA specific for human EGFR (3’ UTR), α3 integrin (ITGA3; s7543), CD151 (s194332), or β4 integrin (ITGB4; s7584) before performing Sdc4 immunoprecipitation and probing for associated receptors. Protein expression in starting cell lysates is shown in Fig. 52A. Results are representative of duplicate experiments with cells transfected with two different siRNA oligos for each targeted protein (see Fig. 52B); F, UM-SCC47 cells were treated for 72 h with either control siRNA (AM4635) or siRNA-specific anti-human Sdc4 (12434), β4 integrin (ITGB4; s7584), α3 integrin (ITGA3; s7543), EGFR (3’ UTR), CD151 (s194332), Sdc2 (s12635), RON (s8996), or ABL1 (s865), then labeled with EdU to quantify DNA synthesis; ***p ≤ 0.001. Western blot inset shows individual receptor expression 72 h after siRNA transfection. Results are representative of duplicate experiments with cells transfected with two different siRNA oligos for each targeted protein. EGFR, epidermal growth factor receptor; RON, récepteur d’origine nantais; Sdc2, syndecan-2; Sdc4, syndecan-4.

---

**J. Biol. Chem. (2022) 298(6) 102029**
receptors in HaCaT cell lysates (cf. Fig. 4C). NOK and HTE
cells express EGFR and the integrins but have undetectable
levels of the Sdc2 and RON, as well as Sdc4, at the cell surface
(Fig. 5B).

**RON and ABL1 suppress activation of p38MAPK**

In the course of these studies, we probed an antibody array
looking for signaling markers that change in SSTN<sub>EGFR</sub>-treated
tumor cells but not normal epithelial cells. This revealed an
upregulation of stress-activated p38MAPK (Fig. 6A) in
the tumor cells treated with SSTN<sub>EGFR</sub> for 24 h. A time course of
SSTN<sub>EGFR</sub> treatment from 15 min to 16 h confirms that
HNSCC and TNBC cells all activate p38MAPK within 15 min
of peptide addition and that activation persists throughout the
entire time course examined, whereas NOKs and
MCF10A cells fail to activate the kinase (Fig. 6, B and C). To
test if activated p38MAPK is responsible for the S-phase arrest
observed when SSTN<sub>EGFR</sub> causes inactivation of RON and
ABL1, UM-SCC47 cells were treated with either SSTN<sub>EGFR</sub>,
RON kinase inhibitor (BMS-777607 or CAS 913376-84-8), or
ABL1 kinase inhibitor (PPY-A or GNF-5) for 3 h in the
presence or absence of p38MAPK inhibitor BIRB-796 (dor-
amapimod). Treatment with either RON or ABL1 kinase in-
hibitor alone activates p38MAPK (Fig. 6A, In-Cell Western)
and blocks EdU incorporation (Fig. 6D), which is fully rescued
by the addition of BIRB-796 (Fig. 6D). Arrest caused by
activating the DDR using HU is not reversed by BIRB-796
**SSTN<sub>EGFR</sub> blocks carcinoma proliferation**

**Figure 6. SSTN-induced cell cycle arrest depends on activated p38MAPK.**

A, quantification of p38MAPK activation by antibody array (pT180/pY182) in nontransformed keratinocytes (HTE, NOK, and HaCaT) and HNSCC cells (UM-SCC47, SCC25) treated with 30 nM SSTNEGFR (left) or in-cell western of UM-SCC47 cells following treatment with SSTNEGFR, RON kinase inhibitors (BMS-777607 or CAS-913376-84-8), or ABL1 inhibitors (GNF-5 or PPY-A) (right); B, detection of pT180/pY182 p38MAPK following treatment with vehicle alone or 30 μM SSTNEGFR in nontransformed NOKs or transformed HNSCC cells; C, in nontransformed (MCF10A) or transformed (MDA-MB-231, MDA-MB-468, SKBr3) mammary epithelial cells; D, EdU-Click-IT-labeled UM-SCC47 cells treated for 3 h with either vehicle (control), 30 μM SSTNEGFR, 3 μM BMS-777607 (RON inhibitor), 0.2 μM PPY-A (ABL1 inhibitor), or 5 mM hydroxyurea (HU) in the presence or absence of 0.1 μM p38MAPK inhibitor BIRB-796 (Bar = 50 μm); E, quantification of EdU incorporation into cells treated with 30 μM SSTNEGFR with or without p38MAPK inhibitors BIRB-796 or Losmapimod for 3 h; ***p < 0.001. EdU, 5-ethynyl-2'-deoxyuridine; HNSCC, head and neck squamous cell carcinoma; HTE, human tonsillar epithelial cell; NOK, normal oral keratinocyte; P38MAPK, p38 mitogen-activated protein kinase.
This reversal extends to each of the representative HNSCC and TNBC cell lines treated with SSTN_{EGFR}, all of which are rescued (Fig. 6E) either with BIRB-796 or another p38MAPK inhibitor, losmapimod (also known as GW856533X, SB856553, or GSK-AHAB).

Discussion
We have defined a novel signaling apparatus organized by Sdc4 that suppresses cell cycle arrest in carcinoma cells, thus allowing their continued proliferation. Disruption of the Sdc4-organized signaling mechanism using a competitor SSTN_{EGFR} peptide leads to a rapid and global arrest of the carcinoma cells throughout the cell cycle. The signaling mechanism builds on a previously described receptor complex found on migrating epithelial cells comprised of the α3β1 integrin and EGFR docked to a juxtamembrane site in the Sdc4 ectodomain and the α6β4 integrin engaged by the Sdc4 cytoplasmic domain (7, 13). Whereas the cells rely on active EGFR kinase within this receptor complex to drive cell migration (36, 50), the proliferation regulatory mechanism described here is independent of EGFR kinase and depends on the incorporation of additional components into the complex, namely, Sdc2, RON, and the RON-associated kinase ABL1. These components appear to be critical for suppressing p38MAPK activity in order to sustain the proliferation of transformed epithelial cells. Although not examined in this study, it is likely that this mechanism is a normal response of epithelial cells to changes in their environment, perhaps coupled to stress signals encountered during migration and wound healing. For example, suspension of epidermal keratinocytes activates p38MAPK, which is suppressed if the cells are allowed to readhere to LN332 via the α3β1 and α6β4 integrins (51).

By suppressing p38MAPK, the syndecan-organized receptor complex may ensure continued DNA synthesis in the tumor cells that are undergoing oncogenic, metabolic, or genotoxic stress (see model, Fig. 7). Increasing evidence suggests that p38MAPK and c-Jun N-terminal kinase stress kinases have significant roles in cell cycle arrest, whether caused by DNA damage or other types of stress (52–54). Although their targets are only now being identified, p38MAPK is known to target p38MAPK-activated protein kinase-2 (MAPK-APK2) that inactivates the cdc25A phosphatase and causes G1- and S-phase arrest (55). Interestingly, prior studies have shown that proliferation of prostate and breast carcinoma cells is enhanced by RON activation of ABL1, which is proposed to phosphorylate tyrosine 211 in proliferating cell nuclear antigen (PCNA), the sliding clamp that assembles the replisome engaged in DNA synthesis (39, 40, 56). Disruption of this event by SSTN_{EGFR} may also have a role in the overall arrest mechanism, although how p38MAPK would be involved in this mechanism is not clear.

How these newly identified receptors are incorporated into the receptor complex remains unknown, but our current data provide a plausible order of assembly (Fig. 4D). The α6β4 integrin binds a motif in the C-terminus of the Sdc4 cytoplasmic domain and there is no evidence to date for an extracellular interaction between this integrin and the syndecan (13, 57). But all of the remaining receptors are displaced from Sdc4 by SSTN_{EGFR}, indicating that they all rely either directly or indirectly on the docking site comprised by amino acids 87 to 131 in the Sdc4 extracellular domain. Sdc4’s interaction with EGFR is direct, as it is known that purified recombinant EGFR and Sdc4 extracellular domains interact directly via this site (7). EGFR, in turn, may recruit the α3β1 integrin contained in a subcomplex consisting of the α3β1 and α6β4 integrins and the tetraspanin CD151 (Fig. 4D), most likely in a specialized, tetraspanin-enriched membrane microdomain (58, 59). Other examples where integrins and kinases are coupled by docking sites in syndecan extracellular domains (e.g., α3β1 and HER2 (7), α4β1 and VEGFR2 (6), αvβ3 and IGF1R (5)) all involve some recognition of the syndecan by both the integrin and the kinase, which suggests α3β1 may depend on a bipartite interaction with EGFR and Sdc4.

Our current evidence strongly suggests that ABL1 engages the cytoplasmic domain of activated RON, which in turn engages a site in the extracellular domain of Sdc2. What remains unknown is the interaction that links Sdc2 to amino acids 87 to 131 in the extracellular domain of Sdc4. The most likely scenario is that Sdc2 also interacts with the α3β1 integrin, perhaps stabilized by an interaction between the α3β1 integrin and RON. This would explain why Sdc2 and its associated kinases are lost from Sdc4 when α3β1 integrin expression is silenced (Fig. 4D). There are likely to be other stabilizing interactions as well. Sdc2 and Sdc4 are known to heterodimerize via interactions within their transmembrane domains (60). RON may also form heterodimers with EGFR (61, 62), potentially further stabilizing the incorporation of Sdc2, RON, and ABL1 into the receptor complex.

RON is activated when incorporated into the receptor complex, presumably by clustering, leading to phosphorylation of ABL1 and the α6β4 integrin. This mimics the activation of HER2, IGF1R, and VEGFR2 when they become engaged with syndecans (5–7). The exception appears to be EGFR, which requires EGF ligand rather than clustering for activation when associated with Sdc4 and integrins (13). Future studies will be required to identify the target of ABL1 that restricts p38MAPK.

**Figure 7. Model.** Model showing the role of the syndecan-organized multi-receptor complex in promoting EGFR kinase–dependent cell invasion and EGFR kinase–independent suppression of stress-induced S-phase arrest in tumor cells. EGFR, epidermal growth factor receptor.
activation, presumably an upstream enzyme in the MAPK signaling cascade, as well as the target of p38MAPK that causes the global arrest.

**Experimental procedures**

**Reagents**

STN<sub>EGFR</sub> peptide consists of amino acids 87 to 131 of human Sdc4 (F94-8RG3) provided by Dr Guido David (University of Leuven) and integrin αβ4 (3E1) from Memorial Sloan-Kettering. Anti-Sdc4 (AF2918), EGFR (AF231), RON (AF691 and FAB6647F), pY1238/1239 RON (AF1947), ITGB4 (mAb 422325) Sdc2 (305515) were from R&D Systems. Anti-ITGA3 (NB2-48514) was from Novus Biologicals. Rabbit mAbs 73E5 (pY245-ABL1), 247C7 (pY412-ABL1), D13E1 (p38MAPK), 11H10 (tubulin), 133D3 (pS345-CHK1), 2661S (pT68-CHK2), D3H8P (PCNA), 1B1B2 (histone H3), 28B10 (pT183/Y185-p38MAPK), and E4I9J (CD151) were from Cell Signaling Technology. Anti-MCM2 (A300-191A) was from Santa Cruz Biotechnology. Anti-Sdc2 (305515) were from R&D Systems. Anti-Sloan-Kettering. Anti-Sdc4 (AF2918), EGFR (AF231), RON (AF691 and FAB6647F), pY1238/1239 RON (AF1947), ITGB4 (mAb 422325) Sdc2 (305515) were from R&D Systems. Anti-ITGA3 (NB2-48514) was from Novus Biologicals. Rabbit mAbs 73E5 (pY245-ABL1), 247C7 (pY412-ABL1), D13E1 (p38MAPK), 11H10 (tubulin), 133D3 (pS345-CHK1), 2661S (pT68-CHK2), D3H8P (PCNA), 1B1B2 (histone H3), 28B10 (pT183/Y185-p38MAPK), and E4I9J (CD151) were from Cell Signaling Technology. Anti-MCM2 (A300-191A) was from Santa Cruz Biotechnology.

**Cell culture**

Parental telomerase reverse transcriptase–immortalized human NOKs and HTEs were described previously (64, 65). HaCaT keratinocytes (CVCL 0038) were provided by Dr Peter LaCelle (Roberts Wesleyan College). Human mammary MCF10A (CVCL 0598), MDA-MB-231 (CVCL 0062), MDA-MB-468 (CVCL 0419) cells, and human SCC25 HNC (CVCL 1682) cells were from ATCC. UM-SCC47 (CVCL 7759), UM-SCC1 (CVCL 7707), TU-138 (CVCL 4910), and 93-VU-147T (CVCL L895) HNC cells were provided through the auspices of the Wisconsin Head and Neck Cancer SPORE. All cells with the exception of the NOKs and HTEs were STR profiled by Genetica LabCorp within 6 months of use. All cells were cultured at 37 °C and 92.5% air/7.5% CO2. NOKs and HTEs were cultured in complete Keratinocyte Serum-Free medium containing 100 units/ml penicillin and 100 μg/ml streptomycin (Life Technologies). All other cell lines were cultured as previously described (5, 7–9). New cultures were reestablished from frozen stocks after a maximum of 3 to 4 months of passage, and all cultures were screened for mycoplasma approximately every 6 months by the Small Molecule Screening Facility in the University of Wisconsin Carbone Cancer Center using the R&D Systems MycoProbe Mycoplasma Detection Kit (Cat. # CUL001B).

**Flow cytometry**

To measure cell surface receptor expression, suspended cells were incubated for 1 h on ice with 1 μg of primary antibody per 5 × 10<sup>5</sup> cells, washed, counterstained with Alexa-488-conjugated goat secondary antibodies, and scanned on a Thermo Fisher Scientific’s Attune NxT bench top cytometer. Cell scatter and PI staining profiles were used to gate live, single-cell events. For cell cycle analysis, asynchronous or synchronous (double thymidine block: 4 mM thymidine for 24 h, followed by 16 h release in culture medium supplemented with 30μM deoxyctydine (D3897, MilliporeSigma), followed by an additional 24 h with 4 mM thymidine) were released from the double thymidine block and treated with STN<sub>EGFR</sub> after cells recovered from the block and entered S-phase. Cells were labeled with 100 μM EdU for 1 h prior to being suspended and fixed in ice-cold 70% ethanol. Cells were first stained using a Click-IT EdU-labeling reaction for 1 h (1.3 mM THPTA/CuSO<sub>4</sub> mix, 20 μM AF488 picolyl azide, and 2.5 mM ascorbic acid in 0.1% Triton X-100) followed by DAPI (D1306) staining for 4 h (5 μg/ml in the presence of 1 μg/ml DNase-free RNase A (Thermo Fisher Scientific) in 0.1% Triton X-100). Cells were then analyzed by flow cytometry to assess levels of AF488-EdU and DAPI staining on a ThermoFisher Attune NxT bench top cytometer.

**Immunoprecipitations and Western blotting**

Immunoprecipitation of the Sdc–receptor tyrosine kinase: ITG complex in the presence or absence of competing STN<sub>EGFR</sub> peptide was carried out using antibodies to Sdc4 or Sdc2 mAb (or mouse IgG1 as a negative control), GammaBind PLUS Sepharose (GE Healthcare Life Sciences), and 1 mg of precleared whole cell lysate (WCL)/sample in the presence of protease and phosphatase inhibitors as previously described (8, 9). For p38MAPK and DDR effector bands, equal amounts of total protein (20–40 μg depending on the target protein and cell line being probed) were loaded per lane. All samples were resolved on 10% Laemmli gels prior to transfer to Immobilon-FL PVDF (MilliporeSigma). Visualization of immunoreactive bands was performed using ECF reagent or direct excitation of fluorescent secondary antibodies on either a GE Healthcare Life Sciences Typhoon Trio or a LI-COR Odyssey Fc Imaging System. For the in-cell western of active p38MAPK, cells were fixed (4% paraformaldehyde), permeabilized (0.3% TX-100), blocked (5% normal goat serum), and then stained for phosphorylated (28B10) and total (D13E1) p38MAPK followed by IR secondary (Li-COR) 800CW for phosphorylated and 680RD for total p38MAPK. Cells were then scanned on a Li-COR Odyssey Aeras flat-top scanner and each cohort was quantitated for the ratio of phosphorylated to total p38MAPK as the fold change (minus background isotype-matched, nonspecific IgG staining) relative to vehicle-treated, control cells.
siRNA design and transfection

Two different siRNAs were used for all treatments with equivalent results, paired with a scrambled siRNA control: Silencer Select control (AM4635) and target-specific siRNA oligos directed against human Sdc4 (siRNA ID # 12434, Target Sequence: 199[ca]GGATACTGTAGCATTTTAGG[A]217 and siRNA ID # s12638, Target Sequence: 536[ct]CTACTGCTCATGTACCG-TA[tt]554; GenBank Accession number NM_002999.4), Sdc2 (siRNA ID # s12635, Target Sequence 996[tt]TGACCTTGGAGAACCGCAA[tt]1014 and siRNA ID # 12636[gt]686[GACAGTC TGTAAAAACGA[tt]886; GenBank Accession Number NM_002999.4), ITGB4 (siRNA ID # s7584, Target Sequence: 658[GCGACTACATAGGATT[tt]676 and siRNA ID # s7585, Target Sequence: 586[ca]CACAATCTCATCGCGATT[tt]598; GenBank Accession Number NM_001005731.3), ITGA3 (siRNA ID # s7543, Target Sequence: 1026[gt]GGACTTATCTGAGTATA[tt]1044 and siRNA ID # s7541, Target Sequence: 2629GTA CTGTACTTCA[tt]428 and siRNA ID# s194332, 3AATCACCGGCTACAAA[tt]2647; GenBank Accession Number NM_005228.5) and human EGFR-specific siRNA oligo (sc-29301) acquired from Santa Cruz Biotechnology, MST1R (siRNA ID # s8996, Target Sequence: 3576[GCCCGAATGATATCA[tt]3594 and siRNA ID # s8998, Target Sequence: 3065[GCGTATGTTGATATGCTA[tt]3084; GenBank Accession Number, NM_002447,ABL1 (siRNA ID # s865, Target Sequence: 2629GTA AATCACCCTGCTACAAA[tt]2647; GenBank Accession Number NM_002024.4), EGFR (3UTR Target Sequence: 1836GAAGGGAGGGTGTACTTCA[tt]1990 and siRNA ID # s864, Target Sequence: 3065GCGTAGATGGTGAATGTCA[tt]3084; GenBank Accession Number NM_002998.4), ITGB4 (siRNA ID # s7584, Target Sequence: 409CTGCTGCGC- CCAA[tt]3594 and siRNA ID# s8996, Target Sequence: 1990GAGGTGAAGGTGACCCATT[tt]1954; GenBank Accession Number NM_007313.3), and CD151 (siRNA ID # s2728, Target Sequence: 409CGTCTGCAGCG- TGCTACTTCA[tt]428 and siRNA ID s194332, 3UTR Target Sequence: 938[ca]CACAATCTCAGGACTGAGA[tt]963; GenBank Accession Number NM_0004357.5) are from Life Technologies.

Cell proliferation assays

Cells (1–2 × 10^4/well) were plated in 96-well plates in complete culture medium in the presence or absence of SSTN_EGFR peptide or EGFR kinase inhibitors for 72 h. Cell numbers were measured using CellTiter-GLO against a standard curve in accordance with the manufacturer’s instructions.

Cell stress and apoptosis marker array

Screening for stress markers activated in cells treated with SSTN_EGFR peptide for 24 h relative to vehicle-treated (50 mM Hepes, pH 7.4) control cells was conducted as previously described (9) using the PathScan Stress and Apoptosis Signaling Antibody Array Kit (Cell Signaling Technology).

Statistical analyses

Statistical analyses using a two-tailed Student’s t test were performed using Excel (Microsoft Office 365). Data that satisfy confidence levels of p ≤ 0.05, 0.01, or 0.001 are noted. Data are presented as means ± SEM, unless otherwise noted.

Data availability

All data described in the article are contained herein.

Supporting information—This article contains supporting information.

Acknowledgments—This work was supported by funds from the UW Head and Neck Cancer SPORE (P50DE026787) and the use of the UW Carbone Cancer Center shared services, supported by P30 CA014520.

Author contributions—D. M. B., S. E. N., and A. C. R. conceptualization; D. M. B., S. E. N., K. M. A., N. A. S., and O. J. investigation; D. M. B., K. M. A., and N. A. S formal analysis; D. M. B. and A. C. R.
**SSTN<sub>EGFR</sub> blocks carcinoma proliferation**

writing—original draft; D. M. B. and A. C. R. writing—review and editing; A. C. R. supervision; A. C. R. funding acquisition.

**Funding and additional information**—This work was supported by funds from the National Institutes of Health to A. C. R. (R01-CA163662, R01-DE028341) and funds in support of head and neck cancer research to A. C. R. from the UW School of Medicine and Public Health and the UW Carbone Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: DDR, DNA damage response; EdU, 5-ethynyl-2′-deoxyuridine; EGFR, epidermal growth factor; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; HTEs, human tonsillar epithelial cells; HU, hydroxyurea; LN332, laminin-332; NOKs, normal oral keratinocytes; P38MAPK, p38 mitogen-activated protein kinase; PCNA, proliferating cell nuclear antigen; RON, Receptor d’Origine Nantais; Sdc2, syndecan-2; Sdc4, syndecan-4; SSTNEGFR, synstatin-<sub>NEGFR</sub>; TNBC, triple-negative breast cancer.

**References**

1. Shen, X., and Kramer, R. H. (2004) Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. *Am. J. Pathol.* **165**, 1315–1329

2. Saxena, M., Liu, S., Yang, B., HAJAL, C., Changede, R., Hu, J., et al. (2017) EGFR and HER2 activate rigidity sensing only on rigid matrices. *Nat. Matter.* **16**, 775–781

3. Miyamoto, S., Teramoto, H., Gutkind, J. S., and Yamada, K. M. (1996) Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. *J. Cell Biol.* **135**, 1633–1642

4. Engel, H. G., Jenabi, J. M., Zhang, J., Keselgoda, N., Shimada, H., May, W. A., et al. (2007) E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. *Cancer Res.* **67**, 3094–3105

5. Beauvais, D. M., and Rapraeger, A. C. (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. *J. Cell Sci.* **123**, 3796–3807

6. Jung, O., Trapp-Stamborski, V., Purushothaman, A., Jin, H., Wang, H., Sanderson, R. D., et al. (2016) Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. *Oncogenesis* **5**, e202

7. Wang, H., Jin, H., and Rapraeger, A. C. (2015) Syndecan-1 and syndecan-4 capture epidermal growth factor receptor family members and the alpha3beta1 integrin via binding sites in their ectodomains: novel synstatins prevent kinase capture and inhibit alpha3beta4-integrin-dependant epithelial cell motility. *J. Biol. Chem.* 290, 26103–26113

8. Beauvais, D. M., Ell, B. J., McWhorter, A. R., and Rapraeger, A. C. (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. *J. Exp. Med.* **206**, 691–705

9. Beauvais, D. M., Jung, O., Yang, Y., Sanderson, R. D., and Rapraeger, A. C. (2016) Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by SynstatinIGF1 inhibits tumor growth. *Cancer Res.* **76**, 4981–4993

10. Rapraeger, A. C. (2013) Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-alphavbeta3 integrin complex in tumorigenesis and angiogenesis. *FEBS J.* **280**, 2207–2215

11. Whiteford, J. R., Xian, X., Chauussade, C., Vanhaesebroeck, B., Nourshargh, S., and Couchman, J. R. (2011) Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD458. *Mol. Biol. Cell.* **22**, 3609–3624

12. Rapraeger, A. C., Ell, B. J., Roy, M., Li, X., Morrison, O. R., Thomas, G. M., et al. (2013) Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between alphavbeta3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. *FEBS J.* **280**, 2194–2206

13. Wang, H., Jin, H., Beauvais, D. M., and Rapraeger, A. C. (2014) Cytoplasmic domain interactions of syndecan-1 and syndecan-4 with alphabeta4 integrin mediate human epidermal growth factor receptor (HER1 and HER2)-dependent motility and survival. *J. Biol. Chem.* **289**, 30318–30332

14. Hynes, N. E., and Lane, H. A. (2005) ErbB receptors and cancer: the complexity of targeted inhibitors. *Nat. Rev. Cancer* **5**, 341–354

15. Hynes, N. E., and MacDonald, G. (2009) ErbB receptors and signaling pathways in cancer. *Curr. Opin. Cell Biol.* **21**, 177–184

16. Scalfiti, M., and Baselga, J. (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. *Clin. Cancer Res.* **12**, 5268–5272

17. Cassell, A., and Grandis, J. R. (2010) Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. *Expert Opin. Investig. Drugs* **19**, 709–722

18. Chung, C. H., Parker, J. S., Karaca, G., Wu, J., Funkhouser, W. K., Moore, D., et al. (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. *Cancer Cell* **5**, 489–500

19. Rubin Grandis, J., Chakraborty, A., Melhem, M. F., Zeng, Q., and Tewary, D. J. (1997) Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. *Oncogene* **15**, 409–416

20. Dent, P., Reardon, D. B., Park, J. S., Bowers, G., Logsdon, C., Valerike, K., et al. (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. *Mol. Biol. Cell* **10**, 2493–2506

21. Schmidt-Ullrich, R. K., Chica, J. R., and Tewary, D. J. (2007) EGF/EGFR stimulates keratinocyte proliferation in response to ectodomain shedding of syndecan-1. *Biochem. J.* **399**, 419–426

22. Zimmersmann, M., Zehetlaier, S., and Oszain, M. (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. *Radiat. Oncol.* **1**, 11

23. Chang, S. S., and Califano, J. (2008) Current status of biomarkers in head and neck cancer. *J. Surg. Oncol.* **97**, 640–643

24. Perez-Onodera, B., Beauchemin, M., and Jordan, R. C. (2006) Molecular biology of squamous cell carcinoma of the head and neck. *J. Clin. Pathol.* **59**, 445–453

25. Carvalho, F. M., Bacchi, L. M., Santos, P. P., and Bacchi, C. E. (2010) Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients. *Clinics (Sao Paulo)* **65**, 1033–1036

26. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000) Molecular portraits of human breast tumours. *Nature* **406**, 747–752

27. Harari, P. M., Wheeler, D. L., and Grandis, J. R. (2009) Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. *Semin. Radiat. Oncol.* **19**, 63–68

28. Ronsin, C., Muscatelli, F., Mattei, M. G., and Breathnach, R. (1993) A novel putative receptor protein tyrosine kinase of the met family. *Oncogene* **8**, 1195–1202

29. Yao, H. P., Zhou, Y. Q., Zhang, R., and Wang, M. H. (2013) MSP-RON signalling in cancer: pathogenesis and therapeutic potential. *Nat. Rev. Cancer* **13**, 466–481

30. Wagh, P. K., Peace, B. E., and Waltz, S. E. (2008) Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. *Adv. Cancer Res.* **100**, 1–33
31. Greubel, E. K., Smith-Pearson, P., Wang, J., and Pendergast, A. M. (2013) Role of ABL family kinases in cancer: from leukemia to solid tumours. *Nat. Rev. Cancer* 13, 559–571.

32. Pardee, A. B. (1989) G1 events and regulation of cell proliferation. *Science* 246, 603–608.

33. Flynn, R. L., and Zou, L. (2011) ATR: a master conductor of cellular responses to DNA replication stress. *Trends Biochem. Sci.* 36, 133–140.

34. Kastan, M. B., and Bartek, J. (2004) Cell-cycle checkpoints and cancer. *Nat. Rev. Cancer* 4, 316–323.

35. Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., et al. (2008) GammaH2AX and cancer. *Nat. Rev. Cancer* 8, 957–967.

36. Mariotti, A., Kedeshian, P. A., Dans, M., Curatola, A. M., Gagnoux-Palacios, L., and Giancotti, F. G. (2001) EGFR-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. *J. Cell Biol.* 155, 447–458.

37. Santoro, M. M., Gaudino, G., and Marchisio, P. C. (2003) The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. *Dev. Cell* 5, 257–271.

38. Yu, P. T., Babicky, M., Jaquish, D., French, R., Marayuma, K., Mose, E., et al. (2012) The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. *Int. J. Cancer* 131, 1744–1754.

39. Zhao, H., Chen, M. S., Lo, Y. H., Waltz, S. E., Wang, J., Ho, P. C., et al. (2014) The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. *Oncogene* 33, 1429–1437.

40. Zhao, H., Ho, P. C., Lo, Y. H., Espejo, A., Bedford, M. T., Hung, M. C., et al. (2012) Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. *PLoS One* 7, e29416.

41. Hantschel, O., and Superti-Furga, G. (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. *Nat. Rev. Mol. Cell Biol.* 5, 33–44.

42. Serru, V., Le Naour, F., Billard, M., Azorsa, D. O., Lanza, F., Boucheix, C., et al. (1999) Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha5beta1) under conditions disrupting tetraspan interactions. *Biochim. J.* 340, 103–111.

43. Yauch, R. L., Berditchevski, F., Harler, M. B., Reichner, J., and Hemler, M. E. (1998) Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. *Mol. Biol. Cell* 9, 2751–2765.

44. Oh, E. S., and Couchman, J. R. (2004) Syndecans-2 and -4: close cousins, but not identical twins. *Mol. Cells* 17, 181–187.

45. Dans, M., Gagnoux-Palacios, L., Blakie, P., Klein, S., Mariotti, A., and Giancotti, F. G. (2001) Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. *J. Biol. Chem.* 276, 1494–1502.

46. Harper, E. G., Alvares, S. M., and Carter, W. G. (2005) Wounding activates p38 map kinase and activation transcription factor 3 in leading keratinocytes. *J. Cell Sci.* 118, 3471–3485.

47. Llopis, A., Salvador, N., Ercilla, A., Guaita-Esteruelas, S., Barrantes Idel, B., Gupta, J., et al. (2012) The stress-activated protein kinases p38alpha/ beta and IN1K2/1 cooperate with Chk1 to inhibit mitotic entry upon DNA replication arrest. *Cell Cycle* 11, 3627–3637.

48. Gryp, J. L., and Gutierrez, G. J. (2012) UnCHKed DNA replication: a stressful matter. *Cell Cycle* 11, 3917–3918.

49. Schramek, D., Kotsinas, A., Meixner, A., Wada, T., Elling, U., Pospisilik, et al. (2011) The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. *Nat. Genet.* 43, 212–219.

50. Reinhardt, H. C., Aslanian, A. S., Lees, J. A., and Yaffe, M. B. (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. *Cancer Cell* 11, 175–189.

51. Zhao, H., Lo, Y. H., Ma, L., Waltz, S. E., Gray, J. K., Hung, M. C., et al. (2011) Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. *Mol. Cancer Ther.* 10, 29–36.

52. Wang, H., Leavitt, L., Ramaswamy, R., and Rapraeger, A. C. (2010) Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. *J. Biol. Chem.* 285, 13569–13579.

53. Hemler, M. E. (2005) Tetraspanins functions and associated microdomains. *Nat. Rev. Mol. Cell Biol.* 6, 801–811.

54. Yanez-Mo, M., Barreiro, O., Gordon-Alonso, M., Sala-Valdes, M., and Sanchez-Madrid, F. (2009) Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. *Trends Cell Biol.* 19, 434–446.

55. Choi, Y., Kwon, M. J., Lim, Y., Yun, J. H., Lee, W., and Oh, E. S. (2015) Trans-regulation of syndecan functions by hetero-oligomerization. *J. Biol. Chem.* 290, 16943–16953.

56. Keller, J., Nimnual, A. S., Shroyer, K. R., Joy, C., Ischenko, I., Chandler, C. S., et al. (2013) Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma. *Br. J. Cancer* 109, 482–492.

57. Harlow, E., and Lane, D. (1998) *Antibodies: A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

58. TSLNEGFR blocks carcinoma proliferation